|
시장보고서
상품코드
2008122
손발톱진균증 치료 시장 : 치료법별, 종류별, 지역별Onychomycosis Treatment Market, By Treatment Type, By Type, By Geography |
||||||
손발톱진균증 치료 시장은 2026년에 37억 5,500만 달러로 추정되며, 2033년까지 54억 9,700만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.6%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 37억 5,500만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 5.60% | 예측 금액(2033년) | 54억 9,700만 달러 |
손발톱진균증은 발톱이나 손발톱에 발생하는 곰팡이 감염으로, 손발톱의 모든 구성요소가 침범될 수 있습니다. 치료에서는 지속적으로 높은 성공률을 유지하고 있기 때문에 약물이 여전히 1차 선택 치료법이 되고 있습니다. 손발톱진균증 치료에서 차세대 경구용 항진균제(이트라코나졸과 테르비나핀)가 기존 치료법을 대체하고 있습니다.
시장 역학
당뇨병 환자의 손발톱진균증 위험과 당뇨병 유병률 증가, 고령 인구 증가, 안전하고 효과적인 치료법에 대한 수요 증가, 새로운 손발톱진균증 치료제 개발에 대한 관심 증가, 손발톱진균증의 잠재적 위협과 사용 가능한 치료법에 대한 인식 증가는 예측 기간 동안 세계 손발톱진균증 치료 시장의 성장을 견인할 것으로 예상되는 주요 요인으로 꼽힙니다. 성장을 견인할 것으로 예상되는 주요 요인입니다.
예를 들어, 2021년 4월 Alembic Pharmaceuticals Limited(Alembic)는 자사의 합작회사인 Aleor Dermaceuticals Limited(Aleor)가 손발톱진균증 치료제인 에피나코나졸 외용액에 대한 간이신약허가신청(ANDA)을 제출했다고 발표했습니다. 신청(ANDA)에 대해 미국 식품의약국(FDA)으로부터 잠정 승인을 받았다고 발표했습니다.
또한, 2020년 10월에는 문디파마가 감염성 질환 치료제 '베타딘(BETADINE)' 시리즈 신제품을 출시했습니다. 베타딘 엠트릭스(BETADINE EMTRIX) 손발톱용 항진균제는 손발톱진균증을 효과적으로 치료하고 정기적으로 사용하면 손발톱의 외관을 개선할 수 있습니다.
본 보고서의 주요 특징
- 세계의 손발톱진균증 치료 시장에 대해 조사 분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 손발톱진균증 치료 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기준으로 정리하여 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계 손발톱진균증 치료 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 손발톱진균증 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 손발톱진균증 치료 시장 : 치료법별(2020-2033년)
제5장 세계의 손발톱진균증 치료 시장 : 종류별(2020-2033년)
제6장 세계의 손발톱진균증 치료 시장 : 지역별(2020-2033년)
제7장 경쟁 구도
제8장 섹션
KSMOnychomycosis Treatment Market is estimated to be valued at USD 3,755 Mn in 2026 and is expected to reach USD 5,497 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,755 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.60% | 2033 Value Projection: | USD 5,497 Mn |
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.
Market Dynamics
Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.
For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.
Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.
Key features of the study
- This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.
Onychomycosis Treatment Market Segmentation
- By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Drugs
- Laser Therapy
- Photodynamic Therapy
- By Type Insights (Revenue, USD Mn, 2020 - 2033)
- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Other Types
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Onychomycosis Treatment Market
- Lumenis Ltd.
- Cipla Ltd.
- Bayer AG
- Johnson & Johnson
- Moberg Pharma AB
- Pfizer Inc.
- Novartis
- Galderma SA
- Reddys Laboratories Ltd.
- Medimetriks Pharmaceuticals Inc.
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Others.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Type
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of onychomycosis around the world
- Availability of alternative treatment options
- Rise in demand for safe/effective onychomycosis treatment
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Onychomycosis Treatment Market, By Treatment Type, 2020-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Laser Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Photodynamic Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
5. Global Onychomycosis Treatment Market By Type, 2020-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Distal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- White Superficial Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Proximal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Other Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
6. Global Onychomycosis Treatment Market By Geography, 2020-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- U.K.
- Germany
- France
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- China
- Japan
- Australia
- India
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- Mexico
- Brazil
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- GCC
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
- South Africa
- Rest of Middle East, and Africa
7. Competitive Landscape
- Lumenis Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moberg Pharma AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddys Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Medimetriks Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
